⌘K
t
Verici Dx plc announced that CEO Sara Barrington will provide a live investor presentation via the Investor Meet Company platform on 22 November 2023 at 17:00 GMT. The presentation will relate to the Company's recent global licensing and commercialisation agreement for Clarava™ with Thermo Fisher Scientific and is open to all existing and potential shareholders.
| Date | 20 Nov 2023 |
| Time | 07:00:06 |
| Category | Miscellaneous |
| ID | 8865T |
Verici Dx plc
("Verici Dx" or the "Company")
Investor Presentation
Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that Sara Barrington, CEO, will provide a live presentation relating to the Company's recent global licensing and commercialisation agreement for its pre-transplant test (Clarava™) with Thermo Fisher Scientific (https://verici-dx-plc.flint-platform.com/regulatory-news/44270), via the Investor Meet Company platform on 22 November 2023 at 17.00 (GMT).
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet VERICI DX PLC via:
https://www.investormeetcompany.com/verici-dx-plc/register-investor
Investors who already follow VERICI DX PLC on the Investor Meet Company platform will automatically be invited.
Enquiries:
|
Verici Dx |
|
|
Sara Barrington, CEO |
Via Walbrook PR |
|
Julian Baines, Chairman |
|
|
|
|
|
Singer Capital Markets (Nominated Adviser & Broker) |
Tel: 020 7496 3000 |
|
Aubrey Powell / Sam Butcher / Jalini Kalaravy |
|
|
|
|
|
Walbrook PR Limited |
Tel: 020 7933 8780 or vericidx@walbrookpr.com |
|
Paul McManus / Sam Allen |
Mob: 07980 541 893 / 07502 558 258 |
About Verici Dx plc www.vericidx.com
Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology, including through collaboration with medical device, biopharmaceutical and data science partners.
The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.